The impact of medication reconciliation and review in patients using oral chemotherapy.
J Oncol Pharm Pract
; 29(2): 270-275, 2023 Mar.
Article
in En
| MEDLINE
| ID: mdl-36729465
ABSTRACT
BACKGROUND AND AIM:
Verifying and reviewing a patients medication list can detect and reduce drug related problems (DRPs). However little is known about its effects in patients using oral chemotherapy. The aim of this study was to evaluate the impact of these interventions and the adapted Medication Appropriateness Index (aMAI) as a tool to carry out a medication review.METHODS:
A case-control study was carried out. The hospital pharmacist performed a medication reconciliation and medication review, using the aMAI tool, in 54 patients starting oral chemotherapy. Discrepancies, DRP's and associated pharmaceutical interventions were reported via the electronic patient record (EPR). After one month, the acceptance rate was measured and the aMAI score recalculated. Kappa statistics were used to test intra- and interrater reliability.RESULTS:
The medication list in the EPR was incomplete in 74,1% of patients with an average of 2.4 errors per patient. After medication review, the aMAI score decreased significantly from 7.2 to 5.4 (SD = 4,7; p <0.001), indicating an improvement in the appropriateness of the drugs patients were taking. Acceptance rates were 41,4% and 53,2% for advices resulting from medication reconciliation and medication review respectively. Kappa values of 0.90 and 0.70 respectively indicate good intra- and interrater reliability. DISCUSSION ANDCONCLUSION:
The study shows that medication reconciliation can identify and address discrepancies. Furthermore, medication review seems to ensure that drug treatment better meets patient needs. The aMAI was a reliable tool. Future research will have to determine the clinical relevance of these interventions.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pharmacy Service, Hospital
/
Medication Reconciliation
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
J Oncol Pharm Pract
Journal subject:
FARMACIA
Year:
2023
Type:
Article
Affiliation country:
Belgium